Research breaks new ground in understanding how a molecular motor generates force

January 14, 2021

A team of biophysicists from the University of Massachusetts Amherst and Penn State College of Medicine set out to tackle the long-standing question about the nature of force generation by myosin, the molecular motor responsible for muscle contraction and many other cellular processes. The key question they addressed - one of the most controversial topics in the field - was: how does myosin convert chemical energy, in the form of ATP, into mechanical work?

The answer revealed new details into how myosin, the engine of muscle and related motor proteins, transduces energy.

In the end, their unprecedented research, meticulously repeated with different controls and double-checked, supported their hypothesis that the mechanical events of a molecular motor precede - rather than follow - the biochemical events, directly challenging the long-held view that biochemical events gate the force-generating event. The work, published in the Journal of Biological Chemistry, was selected as an Editor's Pick for "providing an exceptional contribution to the field."

Completing complementary experiments to examine myosin at the most minute level, the scientists used a combination of technologies - single molecule laser trapping at UMass Amherst and FRET (fluorescence resonance energy transfer) at Penn State and the University of Minnesota. The team was led by muscle biophysicist Edward "Ned" Debold, associate professor in the UMass Amherst School of Public Health and Health Sciences; biochemist Christopher Yengo, professor at Penn State College of Medicine; and muscle biophysicist David Thomas, professor in the College of Biological Sciences at the University of Minnesota.

"This was the first time these two cutting-edge techniques have been combined together to study a molecular motor and answer an age-old question," Debold says. "We've known for 50 years the broad scope of how things like muscle and molecular motors work, but we didn't know the details of how that occurs at the most minute level, the nanoscale motions. It's like we're looking under the hood of a car and examining how the engine works. How does it take the fuel and convert it into work when you press the gas pedal?"

Using his single molecule laser trap assay in his lab, Debold and his team, including graduate students Brent Scott and Chris Marang, were able to directly observe the size and rate of myosin's nanoscale mechanical motions as it interacted with a single actin filament, its molecular partner in force generation. They observed that the force-generating step, or powerstroke, happened extremely fast, almost as soon as it bound to the actin filament.

In parallel experiments using FRET assays, Yengo's team confirmed this fast rate of the powerstroke and with additional studies demonstrated that the key biochemical steps happened subsequently and much more slowly. Further analysis revealed for the first time how these events might be coordinated by the intramolecular motions deep inside the myosin molecule.

"Chris Yengo collected his data separate from mine and we combined and integrated the results," Debold says. "I could see things that he couldn't, and he could see things that I couldn't, and in combination we were able to reveal novel insights into how a molecular motor transduces energy. It was clear that the mechanics happened first followed by the biochemical events."

Highlighting the importance of examining energy transduction at the nanoscale level has very broad implications, Debold explains. "It's not just about how muscle works," he says. "It is also a window into how many motor enzymes within our cells transduce energy, from those that drive muscle contraction to those that cause a cell to divide."

Detailed knowledge about that process could help scientists one day develop treatments for such conditions as heart failure, cancer and more. "If you understand how the molecular motor works, you could use that information to improve function when it's compromised, as in the case of heart failure," Debold says. "Or if you wanted to prevent a tumor cell from dividing, you could use this information to prevent force-generation. Knowing exactly how force-generation occurs could be very useful for somebody trying to develop a drug to inhibit a molecular motor during cell division, and ultimately cancer."
The researchers presented preliminary findings of their groundbreaking discovery last February at the 64th annual meeting of the Biophysical Society and will present a follow-up study next month at the 65th annual meeting, which is the largest gathering of biophysicists from around the world.

University of Massachusetts Amherst

Related Heart Failure Articles from Brightsurf:

Top Science Tip Sheet on heart failure, heart muscle cells, heart attack and atrial fibrillation results
Newly discovered pathway may have potential for treating heart failure - New research model helps predict heart muscle cells' impact on heart function after injury - New mass spectrometry approach generates libraries of glycans in human heart tissue - Understanding heart damage after heart attack and treatment may provide clues for prevention - Understanding atrial fibrillation's effects on heart cells may help find treatments - New research may lead to therapy for heart failure caused by ICI cancer medication

Machining the heart: New predictor for helping to beat chronic heart failure
Researchers from Kanazawa University have used machine learning to predict which classes of chronic heart failure patients are most likely to experience heart failure death, and which are most likely to develop an arrhythmic death or sudden cardiac death.

Heart attacks, heart failure, stroke: COVID-19's dangerous cardiovascular complications
A new guide from emergency medicine doctors details the potentially deadly cardiovascular complications COVID-19 can cause.

Autoimmunity-associated heart dilation tied to heart-failure risk in type 1 diabetes
In people with type 1 diabetes without known cardiovascular disease, the presence of autoantibodies against heart muscle proteins was associated with cardiac magnetic resonance (CMR) imaging evidence of increased volume of the left ventricle (the heart's main pumping chamber), increased muscle mass, and reduced pumping function (ejection fraction), features that are associated with higher risk of failure in the general population

Transcendental Meditation prevents abnormal enlargement of the heart, reduces chronic heart failure
A randomized controlled study recently published in the Hypertension issue of Ethnicity & Disease found the Transcendental Meditation (TM) technique helps prevent abnormal enlargement of the heart compared to health education (HE) controls.

Beta blocker use identified as hospitalization risk factor in 'stiff heart' heart failure
A new study links the use of beta-blockers to heart failure hospitalizations among those with the common 'stiff heart' heart failure subtype.

Type 2 diabetes may affect heart structure and increase complications and death among heart failure patients of Asian ethnicity
The combination of heart failure and Type 2 diabetes can lead to structural changes in the heart, poorer quality of life and increased risk of death, according to a multi-country study in Asia.

Preventive drug therapy may increase right-sided heart failure risk in patients who receive heart devices
Patients treated preemptively with drugs to reduce the risk of right-sided heart failure after heart device implantation may experience the opposite effect and develop heart failure and post-operative bleeding more often than patients not receiving the drugs.

How the enzyme lipoxygenase drives heart failure after heart attacks
Heart failure after a heart attack is a global epidemic leading to heart failure pathology.

Novel heart pump shows superior outcomes in advanced heart failure
Severely ill patients with advanced heart failure who received a novel heart pump -- the HeartMate 3 left ventricular assist device (LVAD) -- suffered significantly fewer strokes, pump-related blood clots and bleeding episodes after two years, compared with similar patients who received an older, more established pump, according to research presented at the American College of Cardiology's 68th Annual Scientific Session.

Read More: Heart Failure News and Heart Failure Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to